Vijay Kumar Pandey

Sep 2006-Mar 2010, PhD, Molecular Medicine， University of Auckland, New Zealand (NZ);

2003, MSc, Microbiology, University of Pune, India;

2000, BSc, Microbiology, Sardar Patel University, India;

Dec 2021- present, Associate Professor, Tsinghua-Berkeley Shenzhen Institute (TBSI), Institute of Biopharmaceutical and Health Engineering (iBHE),Tsinghua Shenzhen International Graduate School (TSIGS), PR China;

May 2019- Nov 2021, Assistant Professor (Tenure-track), TBSI, iBHE, TSIGS, PR China;

Jan 2018-Jun 2019,  Assistant Professor (Research), TBSI, Shenzhen, PR China;

Aug 2010-Dec 2017,  Research fellow; Advisor: Prof. Peter E. Lobie, Cancer Science Institute of Singapore, NUS, Singapore;

Sep 2009-Aug 2010,  Postdoctoral fellow; Advisor: Prof. Paul B. Fisher, Department of Human & Molecular Genetics, Virginia  Commonwealth University (VCU), Virginia, USA;

2004-2006, Research associate; Advisor: Prof. T. S. Sridhar, Triesta Sciences, Healthcare Global (HCG) Enterprises Ltd, Bengaluru, India;

2003-2004, Research associate, Advisor: Prof. Mario Vaz, St. John’s Research Institute, Bengaluru, India;

1. Member of The Endocrine Society

2. American Association for Cancer Research

3. Ad-hoc reviewer for more than 15 academic international journals including Nature Communications, BMC cancer, Frontiers of Oncology, Cancer Molecular Targets and Therapeutics, Pharmacological Research, Seminars in Cancer Biology, Science Translation Medicine.

1. Member of The Endocrine Society

2. American Association for Cancer Research

3. Ad-hoc reviewer for more than 15 academic international journals including Nature Communications, BMC cancer, Frontiers of Oncology, Cancer Molecular Targets and Therapeutics, Pharmacological Research, Seminars in Cancer Biology, Science Translation Medicine.

1. The molecular basis of cancer (ID: 76000123) TBSI

2. Emerging concepts in cancer research (ID: 86001063) SIGS

Supervisor of 05 Ph.D. and 01 master's students

1. Identification and validation of new molecular targets in human malignancies

2. Biology of stem-like cancer cell-related to cell metabolism, metastasis, therapy resistance and tumor recurrence

3. Translational research- development of inhibitory technologies against oncogenic proteins

1. Overseas Research Cooperation Fund Research Cooperation Project (HW2020008);

2. Universities Stable Funding Key Projects (WDZC20200821150704001);

3. City's Key Laboratory and Start-up Projects (ZDSYS20200820165400003)

4. General Project of National Natural Science Foundation of China(82172618)

[1]Pandey, V., Perry, J. K., Mohankumar, K. M., Kong, X. J., Liu, S. M., Wu, Z. S., Mitchell, M. D., Zhu, T. and Lobie, P. E., Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology, 2008. 149(8): p. 3909-19.

[2]Pandey, V., Wu, Z. S., Zhang, M., Li, R., Zhang, J., Zhu, T. and Lobie, P. E., Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res, 2014. 16(5): p. 429.

[3]Pandey, V., Wang, B., Mohan, C. D., Raquib, A. R., Rangappa, S., Srinivasa, V., Fuchs, J. E., Girish, K. S., Zhu, T., Bender, A., Ma, L., Yin, Z., Basappa, Rangappa, K. S. and Lobie, P. E., Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation. Proc Natl Acad Sci U S A, 2018. 115(44): p. E10505-e10514.

[4]Pandey, V., Zhang, M., You, M., Zhang, W., Chen, R., Zhang, W., Ma, L., Wu, Z. S., Zhu, T., Xu, X. Q., and Lobie, P. E., Expression of two non-mutated genetic elements is sufficient to stimulate oncogenic transformation of human mammary epithelial cells. Cell Death Dis, 2018. 9(12): p. 1147.

[5]Tan, Y. Q., Zhang, X., Zhang, S., Zhu, T., Garg, M., Lobie, P. E. and Pandey, V., Mitochondria: The metabolic switch of cellular oncogenic transformation. Biochim Biophys Acta Rev Cancer, 2021. 1876(1): p. 188534.

[6]Cheng F, Wang X, Chiou YS, He C, Guo H, Tan YQ, Basappa B, Zhu T, Pandey V, Lobie PE. Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression. Cell Death Dis. 2022 Mar 25;13(3):265. doi: 10.1038/s41419-022-04700-4. PMID: 35332126; PMCID: PMC8948291.

[7]Bhardwaj V, Tan YQ, Wu MM, Ma L, Zhu T, Lobie PE, Pandey V. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives. Cancer Lett. 2021 Apr 1;502:97-107. doi: 10.1016/j.canlet.2020.12.042. Epub 2021 Jan 8. PMID: 33429007.

[8]Zhuang QS, Sun XB, Chong QY, Banerjee A, Zhang M, Wu ZS, Zhu T, Pandey V, Lobie PE. ARTEMIN Promotes Oncogenicity and Resistance to 5-Fluorouracil in Colorectal Carcinoma by p44/42 MAPK Dependent Expression of CDH2. Front Oncol. 2021 Aug 6;11:712348. doi: 10.3389/fonc.2021.712348. PMID: 34422665; PMCID: PMC8377398.

1. Compounds as modulator of JAK-STAT pathway, methods, and applications thereof---IN324/CHE/2015, US20160214968;

2. Compounds useful in inhibiting human trefoil factor 3---AU2018279609, EP3634966, KR1020200035936, CA3066217, US20200147039, CN111164087, IN201937052422, IL271035, BR112019025797, JP2020522575, WO/2018/226155;

3. Small molecules inhibitors of BCL-2 associated death promoter (BAD) phosphorylation---AU2018256285, SG11201909418W CN110719906, EP3612518, KR1020200029384,BR112019022015, JP2020517745, IL270078, WO/2018/194520, RU2019135562, CA3060939, IN201947046731 US20200131139, MXMX/a/2019/012475